DURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) — Chimerix CMRXa biopharmaceutical company whose mission is to develop medicines that meaningfully improve and prolong the lives of patients suffering from terminal diseases, announced that Chimerix Chief Technology Officer Joshua Allen, Ph.D., today at Cancer Moonshot Brain Cancer Forum will attend the White House in Washington, DC

“Chimerix is ​​deeply committed to its role in providing targeted medicines for primary brain cancer,” said Mike Sherman, Chief Executive Officer of Chimerix. “While survival rates for GBM and DIPG have remained extremely low for decades, recent breakthroughs in precision oncology have given patients renewed hope. We are excited to be attending the Cancer Moonshot Brain Cancers Forum today on this topic, which is vitally important to us.” Patients We Serve. We hope that our participation will help identify new interventions that can accelerate progress and lead to better outcomes for brain cancer patients.”

The purpose of the Cancer Moonshot Brain Cancers Forum is to align on the top challenges that addressing would lead to better outcomes for GBM and DIPG sufferers, identify opportunities to accelerate ongoing efforts, and generate commitments to spur action, hope to awaken and help as models for other rare cancers.

About Chimerix

Chimerix is ​​a biopharmaceutical company with a mission to develop medicines that meaningfully improve and prolong the lives of patients suffering from terminal diseases. The company’s most advanced clinical development program, ONC201, is in development for H3-K27M mutant glioma, a form of high-grade glioma that often includes GBM and DIPG subsets.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those projected. Among the factors and risks that can lead to…